Zanitek

Quick links to important sections

Zanitek

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zanitek

Property Description
Active Ingredients Enalapril, Lercanidipin
Form Oral Tablet
Pharmacological Class Antihypertensive, Fixed-Dose Combination (FDC)
General Purpose Management of essential hypertension (high blood pressure)
Origin Synthetic, Chemically Derived

Zanitek: Defining the Antihypertensive Combination

Zanitek is a synthetic prescription medicine formulated as an oral tablet and classified as an antihypertensive cardiovascular agent. It is specifically designed as a Fixed-Dose Combination (FDC) product for the management of arterial hypertension, commonly known as high blood pressure. Integrating two distinct types of active agents in one pill is a recognized strategy to support patient adherence and simplify the treatment regimen compared to taking two separate tablets.


Composition and Pharmacological Classes

The core composition of Zanitek involves two chemically derived active ingredients: Enalapril (Enalapril maleate) and Lercanidipin (Lercanidipine hydrochloride). These compounds belong to separate, yet complementary, major drug classes. Enalapril is categorized as an Angiotensin-Converting Enzyme Inhibitor (ACEI), a class recognized for lowering blood pressure by inhibiting vasoconstricting hormones. Lercanidipin is a Dihydropyridine calcium channel blocker, and its combination with an ACEI is utilized for its effectiveness in achieving blood pressure targets.


The General Purpose of Zanitek

The general therapeutic purpose of Zanitek is to provide a synergistic effect through its dual mechanism of action to achieve comprehensive and sustained blood pressure reduction. By simultaneously addressing distinct physiological factors that contribute to elevated pressure, this FDC medication helps minimize peripheral vascular resistance, thereby reducing the strain on the circulatory system. Zanitek is intended to help adult patients with essential hypertension maintain consistently lower blood pressure levels to support long-term cardiovascular health.

What side effects are possible with Zanitek?

The safety profile of Zanitek, a fixed-dose combination of Enalapril (an ACE-Inhibitor) and Lercanidipine (a Calcium Channel Blocker), is characterized by officially documented adverse reactions classified by frequency and affected System-Organ Class (SOC) according to regulatory standards.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Listed Effects
Common (ge 1/100 to < 1/10) Headache, Dizziness, Cough, Peripheral oedema, Flushing, Palpitations, Tachycardia.
Uncommon (ge 1/1,000 to < 1/100) Hypotension, Nausea, Abdominal pain, Hyperkalaemia, Renal impairment.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents emphasize the risk of Angioedema (swelling of the face, tongue, glottis, and/or larynx) as a serious adverse reaction associated with the ACE-Inhibitor component, which may occur at any time during treatment, but potentially more often during the initial weeks. Severe Hypotension and Hepatic Failure have also been reported as serious events.

Specific contraindications limit use in patients with a history of ACE-inhibitor-related Angioedema, severe renal impairment (GFR < 30 ml/min), severe hepatic impairment, or certain recent cardiovascular events such as Unstable Angina Pectoris or Myocardial Infarction (within one month). The label also states that grapefruit or grapefruit juice and alcohol consumption should be avoided due to the potential for increased hypotensive effects.

For Population-Specific Safety, use is contraindicated during the second and third trimesters of pregnancy. Special caution is noted for older adults and patients with renal or hepatic impairment.


The safety information structures the risk profile by classifying expected effects and establishing mandatory constraints based on pre-existing conditions and known severe risks, guiding the official boundaries for the medicine’s use.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the Zanitek (Enalapril/Lercanidipin) overdose profile primarily by the risk of profound and sustained circulatory compromise. The most significant documented manifestations include profound hypotension (severely low blood pressure), which can rapidly progress to circulatory shock and subsequent life-threatening sequelae such as acute renal failure, myocardial infarction, or cerebrovascular accident. Heart rate abnormalities, specifically bradycardia (slow) or tachycardia (fast), and drowsiness are also documented clinical presentations. The Enalapril component carries the specific documented risk of hyperkalemia (elevated serum potassium levels).

Any suspected overdose is classified as a potentially severe and life-threatening emergency by regulatory authorities. The official instruction is to seek immediate medical attention. If symptoms include severe hypotension or signs of circulatory collapse, contact emergency services immediately as specialized critical care is required. Management involves symptomatic and supportive treatment, including intravenous volume expansion. Due to the risk of delayed symptoms, hospital monitoring is required for an extended period. No specific antidote is known for the ACE inhibitor component. Patients with impaired renal function may be at increased susceptibility to complications.

Therapeutic Uses of Zanitek

What Zanitek Treats: Main Uses and Benefits

Zanitek (Enalapril/Lercanidipine) is a fixed-dose combination medicine generally used for the long-term management of essential hypertension, a condition commonly characterized by systemic imbalance and heightened physiological activity. This therapeutic approach is considered relevant in clinical settings where patients may require supportive symptom management to help achieve and maintain target blood pressure levels. The primary use is to manage essential hypertension, which is applicable for patients who have been stabilized on the individual components.

The medicine is commonly used in patients whose blood pressure is not adequately controlled by the components as monotherapy, addressing the clinical scenario of inadequate blood pressure control. The continuous management contributes to easing the overall symptom load associated with chronic high blood pressure. The use of two complementary agents supports a sustained reduction in pressure.

This combination is applied in addressing symptoms that create noticeable physiological strain over time. It is commonly used to help mitigate the chronic strain placed on the heart and blood vessels, and plays a role in managing the risk associated with developing complications, such as stroke, heart attack, and the progression of systemic functional stress. This application supports patients who may require additional management and helps with maintaining progress toward specific therapeutic targets.

“The sustained stabilization of pressure helps patients cope more steadily with the underlying condition and assists with maintaining functional stability.”

Quick Fact: Supports Management of Systemic Vascular Strain

Regulatory References

  1. Australian Pharmaceutical Benefits Scheme (PBS)

Eligibility and Restrictions for Use

Who Can and Cannot Use Zanitek? (Population Eligibility)

Eligibility for Zanitek (Enalapril/Lercanidipine) is strictly determined by regulatory labeling, which outlines patient groups permitted, restricted, or prohibited from using the medicine. Zanitek is generally designated for adult patients with essential hypertension who do not present specific exclusionary factors.

Absolute Contraindications

Use is contraindicated for individuals with a history of angioedema related to any previous ACE inhibitor therapy, or those with hereditary or idiopathic angioedema. It is also prohibited due to hypersensitivity to any component of the fixed-dose combination.

Organ Function and Age Restrictions

Zanitek is contraindicated in patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 mL/min), including those undergoing haemodialysis. Use is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established in this population.

Pregnancy and Conditional Use

The medicine is contraindicated during the second and third trimesters of pregnancy and is not recommended in the first trimester or during breastfeeding. Particular caution is required for patients with mild to moderate renal or hepatic dysfunction and specific acute cardiovascular states, such as untreated heart failure or recent myocardial infarction.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documents define specific interaction patterns for Zanitek (Enalapril/Lercanidipine), primarily involving pharmacokinetic and pharmacodynamic mechanisms. The following combinations and substances carry official restrictions as defined in prescribing information:


Contraindicated and Restricted Combinations

Classification Interacting Agents Regulatory Constraint
Contraindicated Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Itraconazole), Ciclosporin/Cyclosporine Prohibited due to significant Lercanidipine exposure increase.
Contraindicated Sacubitril/Valsartan Prohibited due to increased risk of Angioedema.
Contraindicated Aliskiren-containing products Prohibited specifically in patients with Diabetes Mellitus or Renal Impairment.
Prohibited Food Grapefruit or Grapefruit Juice Increases Lercanidipine systemic availability.

Documented Pharmacokinetic and Pharmacodynamic Effects

Co-administration with CYP3A4 Inducers (e.g., Rifampicin) may reduce Lercanidipine plasma levels and efficacy. Conversely, Lercanidipine increases the exposure of agents like Simvastatin and may increase the C max of Digoxin. Pharmacodynamic risks include an augmented risk of hyperkalemia when combined with Potassium-sparing diuretics or Potassium supplements.

Administration Timing Rules

To manage the pharmacokinetic interaction with food, Zanitek must be taken at least 15 minutes before a meal. Additionally, a minimum separation of 36 hours is required between the last dose of Zanitek and the initiation of Sacubitril/Valsartan.

Mechanism of Action

Blocking the Histamine H₂ Receptor

Zanitek functions as a competitive antagonist, interacting directly with the histamine H2 receptors ( H2 R) located on the parietal cells within the stomach lining. By occupying these binding sites, Zanitek prevents the natural ligand, histamine, from docking and initiating its normal signaling function.


Interrupting the Cellular Acid Cascade

This receptor blockade halts the intracellular signaling cascade that is typically mediated by cyclic AMP and normally leads to the activation and mobilization of the acid-secreting pumps ( H^+ / K^+-ATPase). This mechanism modifies early molecular steps, thereby resulting in a reduction in the overall capacity for acid secretion by the parietal cell.


Modulating Gastric Acidity and Volume

By dampening the histamine-dependent acid production pathway, Zanitek induces a core physiological change: a decrease in the concentration of hydrogen ions ( H^+) and a corresponding decrease in the overall volume of the fluid within the stomach lumen. This mechanism alters the internal chemical environment of the gastric contents.

Dosage and Administration Information

Zanitek is administered via the oral route as a film-coated tablet. This medicine is classified as a fixed-dose combination and is generally utilized for the long-term management of essential hypertension.

It is not intended for the initial treatment of high blood pressure; rather, it is used for patients whose blood pressure levels were not adequately maintained when taking the individual components (Enalapril or Lercanidipine) as monotherapy. The available combination strengths are 10 mg/10 mg and 10 mg/20 mg, representing Lercanidipine and Enalapril, respectively.

The standard administration pattern involves taking one tablet once daily. To ensure proper intake and consistent absorption, the tablet must be swallowed whole with water and is to be taken at least 15 minutes before a meal, preferably in the morning. A critical administration restriction is the requirement that the tablet must not be taken with grapefruit or grapefruit juice, as this can significantly affect the intended usage parameters of the medication.

Regarding specific populations, the administration for older adults necessitates that dosage adjustments be guided by an assessment of the patient's renal function. Furthermore, there is no established recommendation for the use of this combination in the pediatric population (under 18 years).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zanitek

The foundational evidence was derived from short-term, double-blind Randomized Controlled Trials (RCTs) that examined responses in the treatment groups. These studies focused on adults diagnosed with Essential Hypertension who were enrolled in studies while not meeting specific blood pressure targets on single-drug treatment.

Research examined blood pressure and other physiological outcomes by monitoring key measurements over defined time intervals, typically ranging from 8 to 12 weeks. The main outcomes studied involved changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Findings describe patterns observed where the FDC was associated with changes in both SBP and DBP over the study period. The results apply only to the populations studied; those with complex pre-existing conditions were often excluded, meaning data for certain groups remain limited.


Studies Examining Long-Term Systemic Goals and Risk Factors

Research exploring the longer-term goals has utilized observational studies and dedicated clinical trials, often following patients for periods of 3 to 12 months. Studies were designed to examine markers that are monitored for physiological strain or stress. These studies explored the FDC's association with various surrogate markers of cardiovascular and renal health, such as Microalbuminuria and measures of Arterial Stiffness.

Duration of Evidence: Long-term Studies and Follow-up

The majority of high-quality comparative evidence is derived from trials with follow-up durations that were limited to a few months. While the individual components belong to drug classes with established evidence on long-term cardiovascular outcomes, dedicated, randomized controlled trials of the specific FDC lasting many years are not fully established. Therefore, there is limited information for long-term outcomes that directly link the FDC to major clinical event reductions. The evidence relies on surrogate markers and short-term data to support initial drug registration.


What Research Gaps and Uncertainty Remain

A key limitation is the reliance on surrogate markers and short-term data, which means that the long-term effects are not fully established. Furthermore, comparative evidence is lacking for the FDC against every other combination therapy available, meaning that detailed data showing how this specific FDC compares to other two-drug regimens is often derived from individual components rather than head-to-head FDC comparisons.

Key Studies & References PBAC Public Summary Document (PSD) - Lercanidipine/Enalapril - March 2008 (Australian Pharmaceutical Benefits Scheme)

Frequently Asked Questions (FAQ)

Common questions about Zanitek (FAQ)

Q: Is Zanitek the same kind of medicine as [similar drug name]?

According to official product information, Zanitek is a Fixed-Dose Combination (FDC) medicine. It contains two distinct active ingredients: Enalapril, an Angiotensin-Converting Enzyme (ACE) inhibitor, and Lercanidipine, a Dihydropyridine calcium channel blocker. This combination of two drug classes determines how it functions compared to other blood pressure treatments.


Q: Is Zanitek safe for use by older adults?

Official regulatory documents note that special caution is required when using this medication in older adults. For this population, dosage guidance must be based on a medical assessment of the patient's renal function (how well the kidneys are working). This specialized assessment informs the prescribing decision.


Q: Does Zanitek carry any specific warnings from the FDA or other agencies? / What is the purpose of the black box warning on Zanitek, if any?

Regulatory information emphasizes serious safety risks, most notably the possibility of Angioedema, which is rapid swelling of the face, throat, or tongue. This serious adverse reaction is associated with the ACE-Inhibitor component of the medicine and can occur at any time during treatment.


Q: Are there any routine tests needed while taking Zanitek?

Official guidance for patients taking the ACE-Inhibitor component of the medicine indicates that routine monitoring of creatinine (a measure of kidney function) and potassium levels is typically recommended as part of medical practice. This testing is often required for those with pre-existing conditions or when adjusting the dose for older adults.


Q: Can I take Zanitek if I have a history of heart disease?

The official product information lists restrictions, including prohibition of use for individuals who have experienced certain recent cardiovascular events. These include Unstable Angina Pectoris or a Myocardial Infarction (heart attack) within the past month. Caution is also advised for patients with other pre-existing heart conditions.


Q: Are there any long-term effects of taking Zanitek for several years?

Studies have limited long-term data directly linking this specific fixed-dose combination (FDC) to major clinical event reductions over many years. The foundational evidence for the FDC relies mostly on shorter-term clinical trials and studies that examine surrogate markers (indirect physiological measurements).


Q: Is Zanitek effective for everyone who takes it?

Official prescribing information indicates that this medicine is approved for patients whose blood pressure was not adequately maintained when they were taking the individual components alone. Like all medicines, individual patient responses can vary, but this medication is specifically targeted for use in those who need a combination therapy to meet their blood pressure goals.


Q: What is Zanitek used for besides the main condition?

Regulatory documents state that Zanitek is indicated only for the treatment of mild to moderate essential hypertension (high blood pressure). Official prescribing information does not list or support any other indications or uses.


Q: How quickly does Zanitek start working after I take it?

The onset of the maximum blood pressure lowering effect is gradual. Official product information suggests that the full therapeutic benefit of the Lercanidipine component may take about two weeks to become fully apparent.


Q: What is the average time it takes to see the full effect of Zanitek?

The maximal antihypertensive effect of Zanitek is not immediate. A gradual approach to dosage adjustment is generally considered because the full effect of the Lercanidipine component may require approximately two weeks to be clearly established.


Q: What happens if I stop taking Zanitek suddenly?

Regulatory safety information indicates that discontinuation of the drug should occur under the guidance of a healthcare professional. Abrupt cessation of the ACE-Inhibitor component may cause a rapid increase in blood pressure (rebound hypertension) or worsen symptoms for patients with certain heart conditions.


Q: Can Zanitek be taken with common over-the-counter pain relievers?

The official interaction warnings note that taking the ACE-Inhibitor component with common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, may carry risks. This combination can potentially reduce the medicine's blood pressure lowering effect and may affect kidney function, particularly in patients who are elderly or already have kidney problems.


Q: Does Zanitek cause weight gain or weight loss?

Neither generalized weight gain nor weight loss is frequently listed as a common side effect of Zanitek. However, official adverse event reporting associated with the ACE-Inhibitor component includes weight gain, typically listed in the context of peripheral swelling or fluid retention related to kidney issues.


Q: Is Zanitek known to cause drowsiness or affect driving?

Dizziness is reported as a common side effect of this medicine. Regulatory information indicates that the medicine may affect a person's alertness or coordination. Patients should be mindful of this potential effect.


Q: Can Zanitek affect sleep patterns?

While general sleep pattern changes are not listed as a common effect, uncommon side effects have been noted that could interrupt sleep. These include disturbances such as nocturia (frequent urination at night).


Q: Is it common to feel worse before feeling better when starting Zanitek?

While the product information does not use this specific phrasing, patients may experience symptomatic low blood pressure (hypotension), which can cause symptoms like faintness or light-headedness. This is more likely to occur during the initial starting period or when the dose is being adjusted.


Q: Is there a generic version of Zanitek available?

Zanitek is the brand name for this medication. However, the fixed-dose combination of its two active ingredients, Enalapril and Lercanidipine, is widely available in many markets around the world under various generic and alternative brand names.


Q: How long does Zanitek stay in your system?

Pharmacokinetic data from official documents shows that the mean terminal elimination half-life for the Lercanidipine component is approximately 6 to 8 hours. The active metabolite of the Enalapril component, called Enalaprilat, has an elimination half-life of about 11 hours.


Q: Does Zanitek affect mood or mental clarity?

Common side effects include headache and dizziness. While mental/mood changes are not common, rare serious adverse effects associated with low blood pressure or kidney function issues, such as confusion, have been reported in regulatory documents.


Q: Is Zanitek addictive or habit-forming?

The active ingredients in Zanitek, Enalapril and Lercanidipine, are not classified as controlled substances by regulatory bodies in the United States or other major health agencies. The medicine is not considered to be addictive or habit-forming.


Q: Can Zanitek interact with aspirin or ibuprofen?

Official interaction warnings state that combining the medicine with anti-inflammatory drugs like ibuprofen or high-dose aspirin may reduce its blood pressure lowering effect. This combination also carries a potential risk of impaired kidney function.


Q: What does the patient information leaflet say about stopping Zanitek?

The safety information included in official patient leaflets advises that abrupt discontinuation of the medication is generally advised against. Any decision regarding cessation or adjustment of the medicine should be made in consultation with a healthcare professional.

How should Zanitek be stored and disposed of?

Storage Requirements

Condition Requirement
Temperature Store below 25 C (not exceeding 77 F).
Protection Protect from both light and moisture to maintain stability.
Packaging Keep the tablets in the original package (blister pack).
Child Safety Must be stored out of the sight and reach of children.
Shelf-Life The official shelf-life is 2 years when stored under the specified conditions.

Disposal Instructions

Official labeling for Zanitek mandates specific procedures for discarding unused or expired product to protect the environment. The medicine must not be disposed of via wastewater or household trash. Instead, any unused quantity should be disposed of according to local regulations, often by returning it to a pharmacist or participating in a community drug take-back program. Following these instructions ensures proper pharmaceutical waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zanitek found in:

A-Z Index: